<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04566393</url>
  </required_header>
  <id_info>
    <org_study_id>ULI-EAP-100</org_study_id>
    <nct_id>NCT04566393</nct_id>
  </id_info>
  <brief_title>Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies</brief_title>
  <official_title>Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>xCures</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Commons</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>xCures</source>
  <brief_summary>
    <textblock>
      The objective of this expanded access program is to provide ulixertinib (BVD-523) for&#xD;
      compassionate use in advanced cancer patients with MAPK pathway-altered solid tumor(s),&#xD;
      including but not limited to KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations who have&#xD;
      incomplete response to or have exhausted available therapies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
  </expanded_access_info>
  <condition>Pancreatic Cancer</condition>
  <condition>Small Bowel Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Melanoma</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Thyroid Cancer</condition>
  <condition>Bladder Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <condition>Cholangiocarcinoma</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Glioblastoma</condition>
  <condition>MAPK Gene Mutation</condition>
  <condition>KRAS Activating Mutation</condition>
  <condition>BRAF Gene Mutation</condition>
  <condition>NRAS Gene Mutation</condition>
  <condition>HRAS Gene Mutation</condition>
  <condition>MEK Mutation</condition>
  <condition>ERK Mutation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ulixertinib (BVD-523)</intervention_name>
    <description>Ulixertinib (BVD-523) is an oral, first-in-class ERK1/2 inhibitor</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Main Inclusion Criterion:&#xD;
&#xD;
             1. Patient has a MAPK pathway-altered solid tumor(s), including but not limited to&#xD;
             KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations.&#xD;
&#xD;
          -  Other Inclusion Criteria:&#xD;
&#xD;
               1. In the opinion of the treating physician, the patient has exhausted or has&#xD;
                  inadequate response to available anti-cancer treatments.&#xD;
&#xD;
               2. In the opinion of the treating physician, the patient has adequate organ function&#xD;
                  to tolerate ulixertinib as defined in section 6.1&#xD;
&#xD;
               3. Male or female patients aged â‰¥ 12 years.&#xD;
&#xD;
               4. Patient must be able to swallow and retain orally administered medication.&#xD;
&#xD;
                  Note: Ulixertinib is primarily absorbed in the duodenum and therefore patients&#xD;
                  with any prior stomach or duodenal resection should be evaluated with that&#xD;
                  understanding.&#xD;
&#xD;
               5. For females, evidence of post-menopausal status or negative urinary or serum&#xD;
                  pregnancy test for pre-menopausal patients.&#xD;
&#xD;
               6. Highly effective contraception for both male and female patients throughout the&#xD;
                  treatment and for at least 4 months after last treatment administration. In&#xD;
                  patients under the age of 18, who are not sexually active, abstinence is an&#xD;
                  acceptable form.&#xD;
&#xD;
               7. Toxicities related to any prior treatments are either stable, stable on&#xD;
                  supportive therapy, resolved, or in the opinion of the treating physician,&#xD;
                  clinically non-significant&#xD;
&#xD;
               8. Ability to understand a written informed consent document, and the willingness to&#xD;
                  sign it. Assent will be obtained when appropriate based on the patient's age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient is already participating in or qualifies for and is able to enroll in a&#xD;
             clinical trial of ulixertinib (BVD-523).&#xD;
&#xD;
          2. Patient has received systemic therapy with an investigational agent within 5&#xD;
             half-lives or 14 days prior to starting ulixertinib treatment, whichever is shorter.&#xD;
&#xD;
          3. Patient has received radiotherapy within 14 days prior to the first dose of&#xD;
             ulixertinib treatment other than for the allowable treatment of symptomatic bone&#xD;
             metastasis.&#xD;
&#xD;
          4. A history of current evidence/risk of retinal vein occlusion (RVO) or central serous&#xD;
             retinopathy (CSR)&#xD;
&#xD;
          5. Current evidence of uncontrolled, significant intercurrent illness that would, in the&#xD;
             treating physician's judgment, contraindicate the patient's treatment with ulixertinib&#xD;
             due to safety concerns.&#xD;
&#xD;
          6. Patients who, in the opinion of the treating physician, have not fully recovered from&#xD;
             recent major surgery to a sufficient extent to tolerate treatment with ulixertinib.&#xD;
&#xD;
          7. Known hypersensitivity to ulixertinib or any component in its formulation.&#xD;
&#xD;
          8. Patients taking prohibited medications as described in current Investigator's&#xD;
             Brochure.&#xD;
&#xD;
             Note: Patients who require treatment with Drugs that are strong inhibitors or inducers&#xD;
             of CYP1A2, CYP2D6, and CYP3A4 (see Appendix 3) were excluded from the FIH study of&#xD;
             ulixertinib and should be discussed with xCures to review if any potential benefits&#xD;
             outweigh the potential risks.&#xD;
&#xD;
          9. Patient is actively breastfeeding.&#xD;
&#xD;
         10. Prior stomach or duodenal resection that in the opinion of the treating physician&#xD;
             would affect the breakdown and absorption of ulixertinib.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>xCures Clinical Operations</last_name>
    <phone>(707) 641-4475</phone>
    <email>expandedaccess@xcures.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Louis B Nabors, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Los Angeles Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Richard M Green, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Michael Demeure, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>xCures Inc.</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Providence Saint John's Health Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Naveed Wagle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Rene Gonzalez-Cotarelo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Benjamin A Weinberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Franciscan Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Meghana Raghavendra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harold Alfond Center for Cancer Care</name>
      <address>
        <city>Augusta</city>
        <state>Maine</state>
        <zip>04330</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Rachit Kumar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer and Leukemia Center</name>
      <address>
        <city>Sterling Heights</city>
        <state>Michigan</state>
        <zip>48314</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Andrew Muskovitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nebraska Cancer Specialists</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Joel M Michalski, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monmouth Medical Center</name>
      <address>
        <city>Long Branch</city>
        <state>New Jersey</state>
        <zip>07740</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Seth Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke Health</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Lars M Wagner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Health Network</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Suresh Nair, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Denton</name>
      <address>
        <city>Denton</city>
        <state>Texas</state>
        <zip>76201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Sharad K Jain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Elena G Chiorean, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 17, 2020</study_first_submitted>
  <study_first_submitted_qc>September 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2020</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

